Charles Schwab Investment Management Inc Monte Rosa Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 311,800 shares of GLUE stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
311,800
Previous 250,582
24.43%
Holding current value
$1.61 Million
Previous $1.77 Million
33.98%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding GLUE
# of Institutions
77Shares Held
40.6MCall Options Held
84.2KPut Options Held
20.6K-
Nea Management Company, LLC Timonium, MD7.69MShares$39.8 Million2.72% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.98MShares$30.9 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$25.4 Million0.24% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.54MShares$23.4 Million0.23% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$13.7 Million0.42% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $242M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...